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Abstract
Background: Aberrant methylation of gene promoter regions has been linked to changes in gene
expression in cancer development and progression. Genes associated with CpG islands (CGIs) are
especially prone to methylation, but not all CGI-associated genes display changes in methylation
patterns in cancers.
Results: In order to identify genes subject to regulation by methylation, we conducted gene
expression profile analyses of an ovarian cancer cell line (OVCAR-3) before and after treatment
with the demethylating agent 5-aza-deoxycytidine (5-aza-dC). An overlapping subset of these genes
was found to display significant differences in gene expression between normal ovarian surface
epithelial cells and malignant cells isolated from ovarian carcinomas. While 40% of all human genes
are associated with CGIs, > 94% of the overlapping subset of genes is associated with CGIs. The
predicted change in methylation status of genes randomly selected from the overlapping subset was
experimentally verified.
Conclusion: We conclude that correlating genes that are upregulated in response to 5-aza-dC
treatment of cancer cell lines with genes that are down-regulated in cancer cells may be a useful
method to identify genes experiencing epigenetic-mediated changes in expression over cancer
development.
Background
Gene expression profiling is now a common first
approach toward the characterization of molecular
changes occurring through cancer development and pro-
gression [1]. While recurrent changes in patterns of gene
expression are beginning to emerge for a variety of can-
cers, the causal basis of the observed differences in expres-
sion remain to be delineated. One characteristic change
associated with many cancers is the down regulation of
genes involved in suppressing malignant transformation.
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Down regulation of these "tumor-suppressor genes" may
occur, not only by genetic (i.e., nucleotide substitution)
changes but also by epigenetic modifications, such as
DNA methylation [2,3]. DNA methylation largely occurs
at cytosines associated with CpG dinucleotides. CpG rich
regions are known as CpG Islands (CGIs). A CGI has been
defined as a region of at least 200 bp with a GC content of
50% or more, and an observed/expected ratio of CpGs
higher than 0.6 [4]. Methylation of CGIs in the promoter
region of genes is known to transcriptionally repress those
genes [3]. Numerous reports have shown that multiple
genes are silenced during cancer progression through
hypermethylation of the CGIs. Some examples of genes
shown to be silenced in ovarian cancers due to hyper-
methylation include OPCML, RASSF1A, BRAC1 and p16
[5-7].
Treatment of cancer cell lines with the demethylating
agent 5-aza-deoxycytidine (5-aza-dC) leads to changes in
gene expression due to the loss of methylation in gene reg-
ulatory regions [8-11]. In this study, an ovarian cancer cell
line (OVCAR-3) was treated with 5-aza-dC to identify
genes regulated in cancer cells by methylation. We com-
pared changes in gene expression patterns in the 5-aza-dC
treated cancer cell line with observed differences in pat-
terns of gene expression between normal and cancerous
ovarian tissue to identify candidate genes undergoing epi-
genetic changes during the process of ovarian cancer
development. The predicted change in methylation status
of genes randomly selected from the list of candidate
genes was experimentally verified. Our results indicate
that correlating genes that are upregulated in response to
5-aza-dC treatment of cancer cell lines with genes that are
down-regulated in ovarian cancers may be a useful
method to identify genes experiencing epigenetic-medi-
ated changes in expression over ovarian cancer develop-
ment.
Results
Gene expression changes in OVCAR-3 in response to 5-
aza-treatment
The ovarian cancer cell line, OVCAR-3, was treated with
five μM 5-aza-dC to identify genes that display a change in
expression in response to changes in methylation. After 72
hours of treatment, RNA was extracted, used to synthesize
biotinylated cRNA, and hybridized to Affymetrix Human
U133 Plus 2.0 oligonucleotide arrays representing
approximately 47,000 transcripts. GC Robust Multiarray
Analysis (GCRMA) signal values were obtained from the
.CEL files as normalized data in log2 format. Analysis of
variance (ANOVA) was applied to identify differentially
expressed genes among the three control and the three 5-
aza-dC treated samples. A total of 831 genes were differ-
entially expressed (p < 0.01) between the control and the
5-aza-dC treated cells, of which 465 were upregulated and
366 were down-regulated. Tables 1 and 2 display the 30
genes with the highest fold changes in expression
(increase or decrease). A higher fold change in expression
was observed for genes upregulated after the treatment
possibly due to the direct effect of loss of methylation in
gene regulatory regions. Among the genes upregulated
after 5-aza-dC treatment were imprinted genes (e.g., H19)
and genes previously reported to be transcriptionally
repressed due to hypermethylation (e.g., CST6  and
SPANX in malignant tissue and MAGEA 1 in non-malig-
nant cells/tissues) [12-14]. Confirmation of the micro-
array results was carried out by RT-PCR of representative
genes that were significantly upregulated in response to
the 5-aza-dC treatment [Cystatin 6 (CST6),  Caveolin-1
(CAV1), Melanoma antigen family A3 (MAGEA3), Chemok-
ine (C-X-C motif) ligand 6 (CXCL6), Aquaporin3 (AQP3),
Stratifin (SFN) and Epithelial membrane protein 3 (EMP3)]
(Figure 1).
Methylation pattern of candidate genes
Genes displaying altered expression levels after 5-aza-dC
treatment could have been directly or indirectly affected
by loss of methylation. Those genes directly affected by 5-
aza-dC would be expected to have a methylated CGI in or
in proximity to promoter regions. Indirect effects might
include the altered expression of loci regulated by genes
containing CGIs. To identify genes associated with CGIs,
we utilized the CGI identification feature of the USCS
Human Genome Browser Gateway. Of the 831 genes dif-
ferentially expressed after 5-aza-dC treatment, 74% are
known to be associated with CGIs.
The methylation pattern of the promoter region of five
genes associated with CGIs and found to be upregulated
after 5-aza-dC treatment (CAV1, CST6, MAGEA3, EMP3
and CXCL6) was examined. With the exception of CXCL6,
all have been previously shown to be hypermethylated in
other cancers or cancer cell lines [12,15-17].
Figure 2 presents the results of sodium bisulfite sequenc-
ing analysis of CpG rich regulatory regions in each of the
five genes. All genes showed extensive methylation of
their promoter regions in the untreated ovarian cancer
cells (OVCAR-3) and a variable decrease of methylation
after 5-aza-dC treatment. CST6,CAV1,EMP3 and MAGEA3
displayed a decrease in methylation ranging from 13% to
61% while CXCL6 exhibited no methylation change in
the promoter region examined. Variability in the response
of different CpG regions to 5-aza-dC has been observed
previously [9,18], therefore we can not exclude the possi-
bility that expression of CXCL6 is controlled by the meth-
ylation levels of a different region than the one studied
here.Molecular Cancer 2007, 6:10 http://www.molecular-cancer.com/content/6/1/10
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Genes responsive to 5-aza-dC in the OVCAR-3 cell line 
display decreased expression in ovarian adenocarcinomas
We hypothesized that if epigenetic mediated changes in
gene expression are occurring in ovarian cancer develop-
ment, at least a subset of the genes upregulated in
response to 5-aza-dC treatment in OVCAR-3 cells should
display lower levels of expression in ovarian adenocarci-
nomas relative to controls. To test this hypothesis, we
looked for overlap between genes responsive to 5-aza-dC
treatment in the OVCAR-3 cells and genes displaying a sig-
nificant change in expression between normal ovarian
surface epithelium brushings (NOSE) and epithelial ade-
nocarcinoma cells isolated from serous papillary epithe-
lial ovarian tumors (EOC) by laser capture
microdissection (LCM). Microarray analysis (Affymetrix
U133 Plus 2.0) was performed on eight samples of NOSE
brushings and eight LCM collections of epithelial cells
from EOC. Differentially expressed genes between these
samples were identified as described for the OVCAR-3 cell
line experiment. Although a comprehensive analysis of
the tissue microarray results will be published elsewhere,
the average fold difference in expression levels between
NOSE and EOC for the overlapping genes (see below) are
presented in Additional File 1.
Of the 831 genes displaying a significant change in expres-
sion in response to 5-aza-dC treatment of OVCAR-3 cells,
123 displayed a significant decrease in expression
between normal ovarian epithelia and adenocarcinomas
[see Additional File 1]. Of these 123 genes, 102 were
upregulated and 21 were down-regulated in response to
the 5-aza-dC treatment in the OVCAR-3 cell line. Included
in the list of 102 genes are genes previously identified as
being hypermethylated and down-regulated in cancer
(e.g., zinc finger protein 185 in prostate cancer [19], CAV1
in breast cancer [20], and DIRAS3 in ovarian cancer [21]).
We thus predicted that the 102 genes upregulated in 5-
aza-dC treated cells that overlapped with genes down-reg-
ulated in EOC were likely to have been so, at least in part,
due to hypermethylation. To determine if these 102 can-
didate genes contained CGIs as our model predicts, we
examined sequences in and immediately flanking each of
the 102 genes. Ninety-six of the 102 candidate genes (94
%) were found to have CGIs. In contrast, it has been esti-
mated that only 40% of all human genes are associated
with CGIs [22].
As an initial experimental test of the model, we randomly
selected two genes from the list of candidate genes (CAV
Table 1: Upregulated genes after 5-aza-dC treatment of OVCAR cells. Chromosomal location and fold change in gene expression are 
shown for 5-aza-dC treated/untreated OVCAR 3 cells.
RefSeq Transcript ID Symbol Gene Name Chr. Fold Change
NM_001351 DAZL Deleted in azoospermia-like 3p24 27.52
NM_052957 ACRC Acidic repeat containing Xq13 27.07
NM_144594 FLJ32942 Hypothetical protein FLJ32942 12q13 22.73
NM_032858 MAEL Maelstrom homolog 1q24 18.75
NM_002364 MAGEB2 Melanoma antigen family B, 2 Xp21 18.73
NM_005363 MAGEA6 Melanoma antigen family A, 6 Xq28 16.31
NM_012253 TKTL1 Transketolase-like 1 Xq28 15.02
NM_023930 KCTD14 Potassium channel tetramerisation domain 11q14 11.34
NM_013453 SPANX Sperm protein associated with the nucleus, X-linked Xq27 10.99
NM_005362 MAGEA3 Melanoma antigen family A, 3 Xq28 10.56
NM_005335 HCLS1 Hematopoietic cell-specific Lyn substrate 1 3q13 10.41
NM_006228 PNOC Prepronociceptin 8p21 9.89
NM_152578 FMR1NB Fragile X mental retardation 1 neighbor Xq27 9.24
NM_005367 MAGEA12 Melanoma antigen family A, 12 Xq28 8.81
NM_003289 TPM2 Tropomyosin 2 (beta) 9p13 7.00
NM_080618 CTCFL CCCTC-binding factor (zinc finger protein)-like 20q13 6.39
NM_001011544 MAGEA11 Melanoma antigen family A, 11 Xq28 6.32
NM_005213 CSTA Cystatin A 3q21 5.80
NR_002196 H19 H19, imprinted maternally expressed untranslated mRNA 11p15 5.71
NM_032048 EMILIN2 Elastin microfibril interfacer 2 18p11 5.41
NM_173571 LOC255313 Hypothetical protein LOC255313 Xq24 5.28
NM_003480 MFAP5 Microfibrillar associated protein 5 12p13 4.79
NM_001323 CST6 Cystatin E/M 11q13 4.79
NM_001327 CTAG1B&A Cancer-testis antigen 1B/cancer-testis antigen 1A Xq28 4.58
NM_001011548 MAGEA4 Melanoma antigen family A, 4 Xq28 4.48
NM_020826 SYT13 Synaptotagmin XIII 11p11 4.37
NM_013238 DNAJC15 DnaJ (Hsp40) homolog, subfamily C, member 15 13q14 4.33
NM_005602 CLDN11 Claudin 11 3q26 4.23
NM_001002915 IGFL2 Insulin growth factor-like family member 2 19q13 4.09
NM_004988 MAGEA1 Melanoma antigen family A, 1 (directs expression of antigen MZ2-E) Xq28 3.73Molecular Cancer 2007, 6:10 http://www.molecular-cancer.com/content/6/1/10
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1 and CXCL6) and one CGI-associated gene not on the list
of candidate genes (EMP3) for sodium bisulfite sequenc-
ing analysis. Consistent with the prediction of the model,
CAV-1 and CXCL6 were found to be hypermethylated in
ovarian cancer relative to control tissues while essentially
no difference in EMP3 methylation pattern was detected.
The observed fold changes in gene expression between
control (NOSE) and ovarian cancer (EOC) samples were
significant (p < 0.01) for CAV 1 (-30.88) and CXCL6 (-
4.22) [see Additional File 1] but not significant (p < 0.06)
for EMP 3 (+1.10). Consistent with these relative changes
in levels of gene expression, the relative increase in levels
of methylation was greater for Cav 1 than CXCL6 and
minimal for EMP3 (Figure 3).
Discussion
The potential contribution of epigenetic changes to cancer
development and progression is a topic of much recent
interest [e.g., [23-25]]. For example, several studies have
implicated changes in DNA methylation with changes in
the expression of a number of putative tumor suppressor
and oncogenes in a variety of cancers [e.g., [2,12-21]]. In
an effort to establish a more global perspective of genes
that may be prone to changes in DNA methylation during
cancer development, a number of investigators have car-
ried out gene profile analyses of a variety of cancer cells
treated with demethylating agents (e.g., 5-aza-dC) [e.g.,
[8-11,26-28]]. The rationale is that genes that are tran-
scriptionally repressed in cancer cells due to hypermethl-
yation may be released from such constraint after
treatment with demethylating agents and thereby identi-
fied by a significant increase in gene expression. If valid,
such a strategy could be useful in identifying a candidate
subset of methylation-regulated genes among the thou-
sands of genes that are typically found to be down-regu-
lated during cancer development. While intuitively
appealing, such a strategy rests upon the questionable
assumption that all or most genes displaying a significant
increase in expression after treatment with demethylating
agents are directly responding to an induced change in
methylation. The purpose of our study was to conduct a
preliminary evaluation of the validity of this assumption
and of the overall utility of this approach within the con-
text of ovarian cancer.
We selected for our study the ovarian cancer cell line
OVCAR 3 because we had previously determined that it
displays a gene expression profile most similar to that of
ovarian cancer epithelial cells (data not shown). Compar-
ing the gene expression profile of OVCAR 3 cells before
and after treatment with 5-aza-dC revealed a significant (p
< 0.01) change in expression for 831 genes. We deter-
Table 2: Downregulated genes after 5-aza-dC treatment of OVCAR cells. Chromosomal location and fold change in gene expression 
are shown for 5-aza-dC treated/untreated OVCAR 3 cells.
RefSeq Transcript ID Symbol Gene Name Chr. Fold Change
NM_0010138360 MAD1L1 MAD1 mitotic arrest deficient-like 1 (yeast) 7p22 -4.27
NM_004883 NRG2 Neuregulin 2 5q31 -3.95
NM_001001331 ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 3p25 -2.88
NM_001719 BMP7 Bone morphogenetic protein 7 (osteogenic protein 1) 20q13 -2.56
NM_032932 RAB11FIP4 RAB11 family interacting protein 4 (class II) 17q11 -2.49
NM_014914 CENTG2 Centaurin, gamma 2 2q37 -2.30
NM_013372 GREM1 Gremlin 1, cysteine knot superfamily, homolog 15q13 -2.28
XM_373734 --- Hypothetical LOC388388 3p13 -2.28
NM_020761 Raptor Raptor 17q25.3 -2.26
NM_001031693 HHLA3 HERV-H LTR-associating 3 --- -2.20
NM_003598 TEAD2 TEA domain family member 2 19q13 -2.18
NM_022773 FLJ12681 Hypothetical protein FLJ12681 16p13.3 -2.18
NM_004389 CTNNA2 Catenin (cadherin-associated protein), alpha 2 2p12 -2.09
XM_032996 MICAL3 Microtubule associated monoxygenase, calponin and LIM domain containing 3 22q11 -2.08
NM_000620 NOS1 Nitric oxide synthase 1 (neuronal) 12q24 -2.06
NM_006567 FARS2 Phenylalanine-tRNA synthetase 2 6p25 -1.20
NM_003466 PAX8 Paired box 8 2q13 -1.99
NM_006613 GRAP GRB2-related adaptor protein-like 17p11 -1.97
NM_022138 SMOC2 SPARC related modular calcium binding 2 6q27 -1.96
NM_017594 DIRAS2 DIRAS family, GTP-binding RAS-like 2 9q22 -1.96
NM_021018 HIST1H3F Histone 1, H3f 6p22 -1.92
NM_004192 ASMTL Acetylserotonin O-methyltransferase-like Xp22 -1.92
NM_002412 MGMT O-6-methylguanine-DNA methyltransferase 10q26 -1.91
NM_001466 FZD2 Frizzled homolog 2 (Drosophila) 17q21 -1.91
XM_498471 LOC147727 Hypothetical protein LOC147727 19p13 -1.90
NM_003562 SLC25A11 Solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11 17p13 -1.88
NM_004565 PEX14 Peroxisomal biogenesis factor 14 1p36 -1.87
NM_003955 SOCS3 Suppressor of cytokine signaling 3 17q25 -1.87
NM_007037 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 11q24 -1.85
NM_022479 WBSCR17 Williams-Beuren syndrome chromosome region 17 7q11 -1.84Molecular Cancer 2007, 6:10 http://www.molecular-cancer.com/content/6/1/10
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mined that 615 of these 831 genes (74%) are associated
with CpG islands (CGIs). This is a substantially higher
fraction than what has been estimated for the human
genome overall (40%) [22], and suggests that, as
expected, CGI-associated genes are especially sensitive to
5-aza-dC treatment. Only slightly more than half (465 or
56%) of the 831 5-aza-dC-responsive genes were signifi-
cantly upregulated after 5-aza-dC treatment as would be
expected if they had been hypermethylated in the cancer
cell. The explanation as to why the remaining 366 genes
displayed a significant decrease in expression after 5-aza-
dC treatment is unknown but could, in part, be due to
hypomethylated CpG-associated genes being accessed by
repressor proteins or to indirect regulatory effects (e.g.,
non-CpG-associated genes responding to an upregulated
repressor protein) or to some unknown gene toxic effect
of the treatment. Regardless, we can conclude that up to
nearly half of the 5-aza-dC responsive genes in the
OVCAR 3 cells may not have been directly responding to
5-aza-dC-induced hypomethylation. On the other hand,
support for the hypothesis that the majority of those genes
upregulated in the cell line after treatment are directly
Methylation analysis of genes upregulated after 5-aza-dC  treatment of the OVCAR-3 cell line Figure 2
Methylation analysis of genes upregulated after 5-
aza-dC treatment of the OVCAR-3 cell line. Summary 
of sodium bisulfite sequencing analysis of CGIs associated 
with the EMP3, CST6, CAV1, MAGEA3 and CXCL6 genes in 5-
aza-dC treated and untreated (control) OVCAR-3 cells. Five 
clones were sequenced for each sample, and each circle dis-
plays the percent methylation of all clones for a single CpG 
dinucleotide (open circle, 100% unmethylated; filled circle, 
100% methylated). Average percent methylation across all 
CpG sites for untreated (control) and 5-aza-dC treated cells 
is shown next to each row of circles. (Vertical bars, CpG dinu-
cleotides; arrow, position of the transcription start site; hori-
zontal black rectangle, region amplified and sequenced after 
sodium bisulfite).
RT-PCR confirmatory analysis of representative genes shown  by microarray analysis to be upregulated after 5-aza-dC  treatment of OVCAR-3 cell line Figure 1
RT-PCR confirmatory analysis of representative 
genes shown by microarray analysis to be upregu-
lated after 5-aza-dC treatment of OVCAR-3 cell line. 
Expression results from the microarray analysis were con-
firmed by RT-PCR for CAV1, SFN, EMP3, CST6, CXCL6 and 
MAGEA3. All the genes showed induction of expression after 
5-aza-dC treatment (AZA) relative to untreated cells (PBS). 
+ and - indicate the presence or absence of reverse tran-
scriptase during cDNA synthesis. GAPDH was used as an 
endogenous control.Molecular Cancer 2007, 6:10 http://www.molecular-cancer.com/content/6/1/10
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responding to 5-aza-dC-induced hypomethylation comes
from the fact that 5 of the 6 upregulated genes that we
directly tested were indeed hypomethylated in response to
the 5-aza-dC treatment.
To evaluate the possible relevance of the results from the
cell line experiment to actual changes in gene expression
that occur during ovarian cancer development, we corre-
lated the OVCAR 3 expression profiles with those from an
ovarian cancer tissue analysis recently completed in our
laboratory. We reasoned that if methylation dependent
changes in gene expression are occurring in ovarian cancer
development, at least a subset of the genes upregulated in
response to 5-aza-dC treatment in OVCAR 3 cells should
display lower levels of expression in ovarian cancer cells
relative to controls. Of the 465 genes upregulated in the
OVCAR 3 experiment, 102 (22%) were found to be down-
regulated in the ovarian cancer cells isolated from tumor
samples. Since 102 genes is a small fraction (~0.02 %) of
the ~5000 genes that were down-regulated in ovarian can-
cer cells and that we estimate that nearly half of these are
associated with CGIs (data not shown), it seems unlikely
that monitoring the gene expression response of OVCAR
3 cells to 5-aza-dC is an effective way to identify all candi-
date genes that may experience functionally significant
changes in methylation over cancer development. How-
Methylation analysis of the EMP3, CAV1 and CXCL6 genes in ovarian cancer (EOC) and control (NOSE) tissues Figure 3
Methylation analysis of the EMP3, CAV1 and CXCL6 genes in ovarian cancer (EOC) and control (NOSE) tissues. 
Summary of sodium bisulfite sequencing analysis of CGIs associated with the EMP3, CAV1 and CXCL6 genes in ovarian ovarian 
cancer and control (NOSE) tissues. For EMP3, 16 clones for 4 cancer samples and 23 clones for 5 control (NOSE) samples 
were sequenced. For CAV 1, 17 clones for 4 cancer samples and 18 clones for 4 control (NOSE) samples were sequenced. For 
CXCL6, 19 clones for 4 cancer samples and 24 clones for 5 normal (NOSE) samples were sequenced. Each circle displays the 
percent methylation of all clones for a single CpG dinucleotide (open circle, 100% unmethylated; filled circle, 100% methyl-
ated). Average percent methylation for cancer (EOS) and control (NOSE) samples is shown next to each row of circles. (Verti-
cal bars, CpG dinucleotides; arrow, position of the transcription start site; horizontal black rectangle, region amplified and 
sequenced after sodium bisulfite).
CXCL6
2.8%
8.2% Cancer
Normal
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52%
27%
EMP3
2%
1%
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Normal
Cancer
NormalMolecular Cancer 2007, 6:10 http://www.molecular-cancer.com/content/6/1/10
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ever, we believe the approach may be useful in identifying
a subset of genes that are most likely to experience func-
tionally significant changes in methylation over cancer
development. This approach can provide researchers with
a useful method by which to identify a candidate set of
genes for detailed epigenetic analysis. Our methylation
analysis of randomly selected genes from the list of 102
overlapping genes, supports our conclusion.
Conclusion
We conclude that correlating genes that are upregulated in
response to 5-aza-dC treatment of cancer cell lines with
genes that are down-regulated in cancer cells may be a use-
ful method to identify genes experiencing epigenetic-
mediated changes in expression over cancer development.
Methods
Cell lines and cell culture
OVCAR-3 cells were grown in RPMI 1640 supplemented
with 20% v/v heat-inactivated FBS (Invitrogen, Carlsbad,
CA), 2 mM L-glutamine (Mediatech Inc., Herndon, VA),
10 mM HEPES buffer (Sigma, St. Louis, MO) penicillin
(100 U/ml), streptomycin (100 μg/ml), 1 mM sodium
pyruvate (Mediatech Inc.), and 0.01 mg/ml bovine insu-
lin (Sigma).
5-aza-dC treatment
OVCAR-3 cells were plated at a concentration of 1 × 106 in
10 cm3 cell culture dishes. Cells were allowed to adhere to
the plates overnight, and the medium was replaced the
next morning. Five μM 5-aza-deoxycytidine (Sigma) or
PBS was added to the medium and the plates were incu-
bated for 3 days at 37°C in a 5% CO2 atmosphere. Each
treatment was done in triplicate.
Microarray
OVCAR-3 cells were washed once in the plate with HBSS
prior to the extraction of RNA and DNA by established
techniques (Trizol). The integrity of the RNA was verified
using an Agilent 2100 Bioanalyzer (Agilent Technologies,
Palo Alto, CA). Biotin labeled cRNA was synthesized,
hybridized to Affymetrix U133 Plus 2.0 oligonucleotide
arrays and analyzed with a GeneChip Scanner 3000
(Affymetrix, Santa Clara, CA).
Microarray data analysis
CEL files generated by the Affymetrix Gene Chip Operat-
ing System (GCOS) were converted to expression level
values using the GCRMA version1.1.0 (ref. below) pack-
age implemented from within the Spotfire DecisionSite
for Microarray Analysis (DSMA). Probe set intensities
Table 3: Primers used for RT-PCR and Sodium Bisulfite sequencing
Gene Primer Sequence Size Tm Ref.
CAV1 RT-PCR_F 5'-CGACCCTAAACACCTCAACGATG-3' 278 55°C [15]
RT-PCR-R 5'-GCAGACAGCAAGCGGTAAAACC-3'
MOD_F 5'-TGTGTATTTTGTAAATATGGTATAATTTG-3' 537 58°C [15]
MOD_R 5'-CATTTTCCCTACTCTAAACCAC-3'
SFN RT-PCR_F 5'-GTGTGTCCCCAGAGCCATGG-3' 161 60°C [23]
RT-PCR-R 5'-ACCTTCTCCCGGTACTCACG-3'
CST6 RT-PCR_F 5'-AAGACCAGGGTCACTGGAGA-3' 163 60°C [12]
RT-PCR-R 5'-CGGGGACTTATCACATCTGC-3'
MOD_F 5'-GGTTGGAATGTTGTAGTGGT-3' 430 55°C [12]
MOD_R 5'-CCCCAACAACAAATACCAA-3'
MAGEA3 RT-PCR_F 5'-TGGAGGACCAGAGGCCCCC-3' 725 68°C [16]
RT-PCR-R 5'-GGACGATTATCAGGAGGCCTGC-3'
MOD_F 5'-AGATTTGGTTTGAGGGGAGTAGAAGT-3' 405 60°C [16]
MOD_R 5'-AACCC(G/A)ACAACAAAAACAACACTAAA-3'
EMP3 RT-PCR-F 5'-TGCTCTCCCTCATTCTCTGCTGTC-3' 274 60°C
RT-PCR-R 5'-CGCTTCCGTAGGTGGATGTAGATG-3'
MOD-F 5'-TAGTATATATTGAGAGGAGGAGAG-3' 340 62°C [17]
MOD-R 5'-CTTCCCAAACTACTACATTCCCA-3'
CXCL6 RT-PCR-F 5'-CCTGAAGAACGGGAAGC- 3' 135 60°C
RT-PCR-R 5'-GACTGGGCAATTTTATGATG-3'
MOD-F 5'-GAGGGATGAATGTAGATAAAGGGAGT-3' 616 60°C
MOD-R 5'-AACTTCCAAATCCAAACAAACTTACTT-3'
GAPDH RT-PCR-F 5'-GAAATCCCATCACCATCTTCCAG-3' 312 56°C
RT-PCR-R 5'-ATGAGTCCTTCCACGATACAAAAG-3'
Size, product size in bp; Tm, annealing temperatureMolecular Cancer 2007, 6:10 http://www.molecular-cancer.com/content/6/1/10
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were filtered with DSMA using a modulation threshold of
5 to include only those probe sets with at least a log base
2 expression value of ≥ 5. Differentially expressed probe
sets were identified using the t-test function of the Profile
Anova Tool of DSMA. SAM (Significance Analysis of
Microarrays v.2.21) was used to calculate fold change val-
ues for the differentially expressed probe sets [29]. Anno-
tations for probe sets were obtained from the NetAffx
website [30].
RT-PCR analysis
1 μg of total RNA was reverse transcribed using oligo (dT)
primers from the Superscript III cDNA synthesis kit (Inv-
itrogen). PCR was performed in an Opticon 2 (MJ
Research) using 1 μl of synthesized cDNA. Primer
sequences and expected length of the products are pro-
vided in Table 3. Gene expression was normalized to the
expression of the housekeeping gene GAPDH.
DNA methylation analysis
Genomic DNA, from 5-aza-dC treated and control
OVCAR 3 cells and NOSE brushings and ovarian cancer
tissues, was treated with sodium bisulfite to convert
unmethylated cytosines to thymines. The EZ DNA Meth-
ylation-Gold Kit (Zymo, Orange, CA) was used to modify
500 ng to 1 μg of DNA. PCR conditions and primer
sequences are provided in Table 3. PCR fragments were gel
extracted using the Tissue DNA Extraction Kit (Qiagen)
and cloned into pCR 2.1-TOPO TA cloning vectors (Invit-
rogen). For the OVCAR 3 treated and untreated cell lines,
5 clones each were extracted using the Qiaprep Spin Min-
iprep Kit (Qiagen) and sequenced (University of Georgia,
DNA sequencing Facility). Eighteen to 24 clones from 4 ×
5 NOSE (control) samples and 16–19 clones from four
cancer samples were sequenced by High-Throughput
Sequencing Solutions at the University of Washington.
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